- Current report filing (8-K)
May 18 2009 - 5:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 17, 2009
IDM PHARMA, INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
0-19591
|
|
33-0245076
|
(State or Other Jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of Incorporation)
|
|
File Number)
|
|
Identification No.)
|
|
|
|
9 Parker, Suite 100
Irvine, California
(Address of principal executive offices)
|
|
92618
(Zip Code)
|
Registrants telephone number, including area code
(949) 470-4751
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
TABLE OF CONTENTS
Item 1.01. Entry into a Material Definitive Agreement.
On May 18, 2009, IDM Pharma, Inc. (
IDM
), entered into an Agreement and Plan of Merger (the
Merger Agreement
) with Takeda America Holdings, Inc., a New York corporation (
Takeda America
)
and Jade Subsidiary Corporation, a Delaware corporation and wholly owned subsidiary of Takeda
America (
Purchaser
), pursuant to which, among other things, Purchaser has agreed to commence a
tender offer for all the outstanding shares of common stock of IDM, subject to the terms and
conditions contained in the Merger Agreement.
On May 18, 2009, Takeda Pharmaceutical Company Limited, a corporation organized under the laws of
Japan and the parent of Takeda America (
TPC
) and IDM issued a joint press release relating to the
Merger Agreement. A copy of the press release was previously furnished by IDM on a Schedule
14D-9C, filed with the Securities and Exchange Commission (
SEC
) on May 18, 2009.
Merger Agreement
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions contained
therein, Purchaser is obligated to commence a tender offer (the
Offer
) to acquire all outstanding
shares of IDM common stock, par value $0.01 per share (the
Shares
) for $2.64 per Share, net to
the seller in cash (the
Offer Price
).
The Merger Agreement provides that Purchaser will commence the Offer as promptly as reasonably
practicable (but no later than seven business days) after the initial public announcement of the
execution of the Merger Agreement. The initial expiration date of the Offer is 20 business days
following the commencement of the Offer, and the Offer may be extended under certain circumstances
described in the Merger Agreement. Under no circumstances may the Offer be extended beyond July
22, 2009. Purchasers obligation to accept for payment and pay for Shares tendered in the Offer is
subject to certain conditions, including, among other things, that at least a majority of the
outstanding Shares on a fully diluted basis (which includes Shares that are issuable pursuant to
outstanding IDM warrants and options) shall have been validly tendered (and not properly withdrawn)
in accordance with the terms of the Offer (the
Minimum Condition
). Pursuant to the Merger
Agreement, as soon as practicable after Purchasers acceptance of Shares tendered in the Offer, and
subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement,
Purchaser is obligated to acquire all of the Shares that were not tendered, through a merger of
Purchaser with and into IDM with IDM being the surviving corporation and a wholly owned subsidiary
of Takeda America (the
Merger
). At the effective time of the Merger, each issued and outstanding
Share (other than Shares held by stockholders who have perfected their statutory rights of
appraisal under Section 262 of the Delaware General Corporation Law) will be automatically canceled
and converted into the right to receive the Offer Price.
The Merger Agreement grants Purchaser an option (the
Top-Up Option
) to acquire directly from IDM
a number of newly-issued Shares equal to the lesser of (i) the number of Shares that, when added to
the number of Shares owned by Purchaser as of immediately prior to the exercise of the Top-Up
Option , constitutes one share more than 90% of the number of Shares that would be outstanding
immediately after the issuance of all Shares subject to the Top-Up Option or (ii) the aggregate
number of Shares that IDM is authorized to issue under its Amended and Restated Certificate of
Incorporation, as amended, but that are not issued and outstanding or otherwise committed to be
issued at the time of exercise of the Top-Up Option.
The Merger Agreement includes customary representations, warranties and covenants of IDM, Takeda
America and Purchaser, including certain operating covenants related to IDMs business. IDM has
also agreed not to solicit, initiate, knowingly encourage or knowingly facilitate any third party
acquisition proposals for IDM. The Merger Agreement also includes termination provisions for both
IDM and Takeda America and provides that, in connection with the termination of the Merger
Agreement under specified circumstances, IDM will be required to pay to Takeda America a
termination fee of $2.25 million, subject to offset by any expense reimbursement amounts previously
paid by IDM. IDM will be obligated to reimburse Takeda Americas actual expenses of up to $750,000
in connection with the termination of the Merger Agreement under specified circumstances.
The closing of the Merger is subject to customary closing conditions. Depending on the number of
Shares held by Purchaser after Purchasers acceptance of the Shares tendered in accordance with the
terms of the Offer (and, if
applicable, Purchasers acquisition of Shares pursuant to the Top-Up
Option), approval of the Merger by the holders of the outstanding Shares after the completion of
the Offer may be required.
A copy of the Merger Agreement is attached as Exhibit 2.1 to this report and is incorporated herein
by reference. The foregoing description of the Merger Agreement does not purport to be complete and
is qualified in its entirety by reference to the Merger Agreement.
The Merger Agreement has been included to provide investors and stockholders with information
regarding its terms. It is not intended to provide any other factual information about IDM. The
Merger Agreement contains representations and warranties that the parties to the Merger Agreement
made to (and solely for the benefit of) each other. The assertions embodied in the representations
and warranties of IDM are qualified by information contained in the confidential disclosure
schedules that IDM delivered in connection with signing the Merger Agreement as well as by
information contained the Annual Report on Form 10-K for the fiscal year ended December 31, 2008,
as amended by the Annual Report on Form 10-K/A and the Quarterly Report on Form 10-Q for the
quarter ended March 31, 2008 (the
SEC Reports
). Accordingly, investors and stockholders should
not rely on such representations and warranties as characterizations of the actual state of facts
or circumstances described therein. Moreover, information concerning the subject matter of such
representations and warranties may change after the date of the Merger Agreement, which subsequent
information may or may not be fully reflected in the parties public disclosures.
Stockholders Agreement
In connection with the Offer, Takeda America and certain of IDMs stockholders (the
Signing
Stockholders
) have entered into a Stockholders Agreement, dated as of May 18, 2009 (the
Stockholders Agreement
). As of May 18, 2009, the outstanding Shares subject to the Stockholders
Agreement represent approximately 55% of the total outstanding Shares and approximately 49% of
Shares outstanding on a fully diluted basis for purposes of determining the Minimum Condition.
Pursuant to the Stockholders Agreement, each of the Signing Stockholders agreed, in their
capacities as stockholders of IDM, among other things, (i) subject to the termination of the
Stockholders Agreement, to tender or cause to be tendered in the Offer all Shares beneficially
owned or subsequently acquired by them, (ii) for the Signing Stockholders who are directors and
officers of IDM, not to withdraw the Shares tendered by them in the Offer prior to the termination
of the Stockholders Agreement, (iii) for Palo Alto Investors, LLC and its affiliates funds, not to
withdraw the Shares tendered by them in the Offer prior to the earliest of (1) the time Purchaser
accepts Shares for payment in the Offer, (2) July 22, 2009, (3) the occurrence of a Company Adverse
Recommendation Change (as defined in the Merger Agreement), (4) the receipt or announcement of an
unsolicited offer to acquire IDM from a third party at a higher price than the Offer Price that is
reasonably capable of being completed or (5) the termination of the Stockholders Agreement, (iv)
for Medarex, Inc., not to withdraw the Shares tendered by them in the Offer prior to the earliest
of (1) the time Purchaser accepts Shares for payment in the Offer, (2) July 22, 2009, (3) the
occurrence of a Company Adverse Recommendation Change (as defined in the Merger Agreement or (4)
the termination of the Stockholders Agreement. The Stockholders Agreement will terminate upon
the earliest of (i) the termination of the Merger Agreement in accordance with its terms, (ii) any
amendment, waiver or modification to the Merger Agreement made without the IDM stockholders prior
written approval that changes the form of the Offer Consideration (as defined in the Merger
Agreement), decreases the amount of the Offer Consideration, extends the outside date for
acceptance of Shares in the Offer, adds additional conditions to the Offer or otherwise materially
and adversely affects IDMs stockholders and (iii) the time Purchaser accepts Shares for payment in
the Offer.
The form of the Stockholders Agreement is filed as Exhibit 99.1 to this report and is incorporated
by reference herein. The description of the Stockholders Agreement set forth above does not
purport to be complete and is qualified in its entirety by reference to the Stockholders
Agreement.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers.
On May 17, 2009, the IDM Board of Directors (the
Board
), in connection with its approval of the
Merger Agreement, approved the following matters:
Vesting Acceleration of Options, Restricted Stock Awards and RSUs
Assuming the satisfaction of the Minimum Condition and Purchasers acceptance and payment for
Shares in the Offer (the
Acceptance Time
), the Board approved the full acceleration of vesting
for all outstanding options to purchase Shares (the
Options
) under IDMs 1989 Stock Plan, as
amended, and IDMs 2000 Stock Plan, as amended (the
Option Plans
), contingent and effective
immediately prior to the Acceptance Time. In addition, the Board approved an amendment to provide
that each Option with an exercise price below the Offer Price shall be amended to provide for a
net exercise or cashless exercise provision so that IDM will reduce the number of Shares
issuable upon exercise of each such Option by the number of Shares equal to the original exercise
price of such Options multiplied by the number of Shares underlying such Option. The foregoing
acceleration of vesting and amendment will apply to Options held by certain of our executive
officers and directors.
In addition, the Board approved and confirmed the acceleration of the vesting of each restricted
stock award and each deferred issuance restricted stock unit award (the
RSUs
) of IDM under the
Option Plans effective and contingent upon the closing of the Merger. Upon the closing of the
Merger, each Share subject to the RSUs shall be cancelled in exchange for the Offer Price. The
foregoing acceleration of vesting will apply to restricted stock awards and RSUs held by certain of
our executive officers and directors and the potential payments related to such acceleration will
be included in the Solicitation/Recommendation Statement on Schedule 14D-9 that IDM expects to file
with respect to the Offer.
Amendment of 2009 Transaction Bonus Plan
The Board adopted IDMs 2009 Transaction Bonus Plan on December 11, 2008 (as amended, the
Transaction Bonus Plan
), which provides for bonus payments to IDMs executive officers in the
event of certain corporate transactions. On May 17, 2009, the Board approved certain amendments to
the Transaction Bonus Plan to clarify that transactions such as the Merger shall be included in the
definition of Change of Control (as defined in the Transaction Bonus Plan) and that the bonus
payments under the Transaction Bonus Plan will be payable upon the closing of any Change of Control
on or prior to August 31, 2009. These bonus payments would be in addition to any payment to which
the specified participants under the Transaction Bonus Plan are entitled under any other agreements
with IDM.
A summary of the Transaction Bonus Plan, as amended, is filed as Exhibit 10.1 to this report and is
incorporated by reference herein. The description of the Transaction Bonus Plan set forth above
does not purport to be complete and is qualified in its entirety by reference to the Transaction
Bonus Plan.
Termination of Directors Deferred Compensation Plan
The Board also approved the termination of IDMs Amended and Restated Directors Deferred
Compensation Plan (the
Directors Deferred Compensation Plan
), contingent and effective upon the
closing of the Merger, and the payment of all benefits under the Directors Deferred Compensation
Plan to the participant directors in that plan in a single lump sum in accordance with applicable
requirements related to Section 409A of the Internal Revenue Code of 1986, as amended. Mike Grey
and John McKearn, who are directors of IDM, will be entitled to receive approximately $126,826 and
$18,242, respectively, in connection with the acceleration of payment of such directors Directors
Deferred Compensation Plan accounts.
Item 9.01. Financial Statements and Exhibits.
2.1
|
|
Agreement and Plan of Merger, dated May 18, 2009, by and among Takeda America Holdings, Inc.,
Jade Subsidiary Corporation and IDM Pharma, Inc.
|
|
10.1
|
|
2009 Transaction Bonus Plan, as amended on May 17, 2009.
|
|
99.1
|
|
Stockholders Agreement, dated May 18, 2009, by and among Takeda America Holdings, Inc. and
certain stockholders of IDM Pharma, Inc.
|
|
99.2
|
|
Joint press release of Takeda Pharmaceutical Company Limited and IDM Pharma, Inc. dated May
18, 2009 (incorporated herein by reference to the Joint Press Release filed under the cover of
Schedule 14D- 9C by IDM Pharma, Inc. on May 18, 2009).
|
Additional Information and Where To Find It
This report is neither an offer to purchase nor a solicitation of an offer to sell Shares of IDM.
The tender offer for the Shares of IDM has not commenced. Stockholders of IDM are urged to read the
relevant tender offer documents when they become available because they will contain important
information that stockholders should consider before making any decision regarding tendering their
Shares. At the time the Offer is commenced, Takeda America and Purchaser will file a Tender Offer
Statement on Schedule TO and related tender offer materials with the SEC, and IDM will file a
Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the Offer. The tender offer
materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer
documents) and the Solicitation/Recommendation Statement will contain important information, which
should be read carefully before any decision is made with respect to the tender offer. The Offer to
Purchase, the related Letter of Transmittal and certain other offer documents, as well as the
Solicitation/Recommendation Statement, will be made available to all stockholders of IDM at no
expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be
made available for free at the SECs website at http://www.sec.gov. In addition, stockholders will
be able to obtain a free copy of these documents (when they become available) at
www.idm-pharma.com.
Safe Harbor for Forward-Looking Statements
This report includes forward-looking statements that are subject to risks, uncertainties and other
factors, including the risks that the acquisition of IDM will not be consummated as the
transactions are subject to certain closing conditions. All statements other than statements of
historical fact are statements that could be deemed forward-looking statements, including
statements regarding the anticipated timing of completion of the transactions; the ability to
complete the transactions considering the various closing conditions; any statements of expectation
or belief; and any statements of assumptions underlying any of the foregoing. These and other
risks affecting IDM and its drug development programs, intellectual property rights, personnel and
business are more fully discussed in IDMs annual report on Form 10-K, quarterly reports on Form
10-Q and other filings made with the SEC. IDM expressly disclaims any intent or obligation to
update these forward-looking statements, except as required by law.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
IDM PHARMA, INC.
|
|
Date: May 18, 2009
|
By:
|
/s/ Robert J. De Vaere
|
|
|
|
Robert J. De Vaere
|
|
|
|
Senior Vice President, Finance and Administration
and Chief Financial Officer
|
|
INDEX TO EXHIBITS
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
2.1
|
|
Agreement and Plan of Merger, dated May 18, 2009, by and among Takeda America Holdings, Inc.,
Jade Subsidiary Corporation and IDM Pharma, Inc.
|
|
|
|
10.1
|
|
2009 Transaction Bonus Plan, as amended on May 17, 2009.
|
|
|
|
99.1
|
|
Stockholders Agreement, dated May 18, 2009, by and among Takeda America Holdings, Inc. and
certain stockholders of IDM Pharma, Inc.
|
|
|
|
99.2
|
|
Joint press release of Takeda Pharmaceutical Company Limited and IDM Pharma, Inc. dated May
18, 2009 (incorporated herein by reference to the Joint Press Release filed under the cover of
Schedule 14D- 9C by IDM Pharma, Inc. on May 18, 2009).
|
Idm Pharma (NASDAQ:IDMI)
Historical Stock Chart
From Apr 2024 to May 2024
Idm Pharma (NASDAQ:IDMI)
Historical Stock Chart
From May 2023 to May 2024